Eletriptan for acute migraine

Migraine is a significant health problem affecting about 18% of women and 6% of men, and many drugs are available for its treatment. Eletriptan is a new drug which will soon be available by prescription. Data from trials undertaken by the manufacturer and analysed independently by the reviewers show...

Full description

Saved in:
Bibliographic Details
Published in:Cochrane database of systematic reviews 2001-07, Vol.2001 (3)
Main Authors: Smith, Lesley A, Oldman, Anna, McQuay, Henry J, Moore, R Andrew, Derry, Sheena
Format: Article
Language:English
Subjects:
Medicine General & Introductory Medical Sciences
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3472-ea072def75827c026fdff2153e5e666f41d6c52752eefa5e5eedb942caacc0893
cites
container_end_page
container_issue 3
container_start_page
container_title Cochrane database of systematic reviews
container_volume 2001
creator Smith, Lesley A
Oldman, Anna
McQuay, Henry J
Moore, R Andrew
Derry, Sheena
description Migraine is a significant health problem affecting about 18% of women and 6% of men, and many drugs are available for its treatment. Eletriptan is a new drug which will soon be available by prescription. Data from trials undertaken by the manufacturer and analysed independently by the reviewers showed that treatment of an acute migraine attack with eletriptan 20 mg, 40 mg or 80 mg provided significant pain relief from 0.5 to 24 hours. The incidence of adverse effects was dose‐related, with patients taking eletriptan 80 mg reporting more adverse effects.
doi_str_mv 10.1002/14651858.CD003224.pub2
format article
fullrecord <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6564092</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_6564092</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3472-ea072def75827c026fdff2153e5e666f41d6c52752eefa5e5eedb942caacc0893</originalsourceid><addsrcrecordid>eNpVzstKxDAYBeAgiDOOPoLSF2hN_tw3gtTxAgNuFNyFTPpnjPRG2hF8ewu6cXXgfHA4hFwzWjFK4YYJJZmRpqrvKeUAohqPezgh6wVsKSx_X5Hzafpc0DJmzsiKacWVZmZNrrYtzjmNs--LOOTCh-OMRZcO2aceL8hp9O2El3-5IW8P29f6qdy9PD7Xd7sycKGhRE81NBi1NKADBRWbGIFJjhKVUlGwRgUJWgJi9HJpsdlbAcH7EKixfENuf3eX4x02Afs5-9aNOXU-f7vBJ_df-vThDsOXU1IJaoH_ACZTTE4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Eletriptan for acute migraine</title><source>Alma/SFX Local Collection</source><creator>Smith, Lesley A ; Oldman, Anna ; McQuay, Henry J ; Moore, R Andrew ; Derry, Sheena</creator><creatorcontrib>Smith, Lesley A ; Oldman, Anna ; McQuay, Henry J ; Moore, R Andrew ; Derry, Sheena</creatorcontrib><description>Migraine is a significant health problem affecting about 18% of women and 6% of men, and many drugs are available for its treatment. Eletriptan is a new drug which will soon be available by prescription. Data from trials undertaken by the manufacturer and analysed independently by the reviewers showed that treatment of an acute migraine attack with eletriptan 20 mg, 40 mg or 80 mg provided significant pain relief from 0.5 to 24 hours. The incidence of adverse effects was dose‐related, with patients taking eletriptan 80 mg reporting more adverse effects.</description><identifier>EISSN: 1469-493X</identifier><identifier>DOI: 10.1002/14651858.CD003224.pub2</identifier><identifier>PMID: 17636718</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Medicine General &amp; Introductory Medical Sciences</subject><ispartof>Cochrane database of systematic reviews, 2001-07, Vol.2001 (3)</ispartof><rights>Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd. 2019 The Cochrane Collaboration</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3472-ea072def75827c026fdff2153e5e666f41d6c52752eefa5e5eedb942caacc0893</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids></links><search><creatorcontrib>Smith, Lesley A</creatorcontrib><creatorcontrib>Oldman, Anna</creatorcontrib><creatorcontrib>McQuay, Henry J</creatorcontrib><creatorcontrib>Moore, R Andrew</creatorcontrib><creatorcontrib>Derry, Sheena</creatorcontrib><title>Eletriptan for acute migraine</title><title>Cochrane database of systematic reviews</title><description>Migraine is a significant health problem affecting about 18% of women and 6% of men, and many drugs are available for its treatment. Eletriptan is a new drug which will soon be available by prescription. Data from trials undertaken by the manufacturer and analysed independently by the reviewers showed that treatment of an acute migraine attack with eletriptan 20 mg, 40 mg or 80 mg provided significant pain relief from 0.5 to 24 hours. The incidence of adverse effects was dose‐related, with patients taking eletriptan 80 mg reporting more adverse effects.</description><subject>Medicine General &amp; Introductory Medical Sciences</subject><issn>1469-493X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNpVzstKxDAYBeAgiDOOPoLSF2hN_tw3gtTxAgNuFNyFTPpnjPRG2hF8ewu6cXXgfHA4hFwzWjFK4YYJJZmRpqrvKeUAohqPezgh6wVsKSx_X5Hzafpc0DJmzsiKacWVZmZNrrYtzjmNs--LOOTCh-OMRZcO2aceL8hp9O2El3-5IW8P29f6qdy9PD7Xd7sycKGhRE81NBi1NKADBRWbGIFJjhKVUlGwRgUJWgJi9HJpsdlbAcH7EKixfENuf3eX4x02Afs5-9aNOXU-f7vBJ_df-vThDsOXU1IJaoH_ACZTTE4</recordid><startdate>20010723</startdate><enddate>20010723</enddate><creator>Smith, Lesley A</creator><creator>Oldman, Anna</creator><creator>McQuay, Henry J</creator><creator>Moore, R Andrew</creator><creator>Derry, Sheena</creator><general>John Wiley &amp; Sons, Ltd</general><scope>5PM</scope></search><sort><creationdate>20010723</creationdate><title>Eletriptan for acute migraine</title><author>Smith, Lesley A ; Oldman, Anna ; McQuay, Henry J ; Moore, R Andrew ; Derry, Sheena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3472-ea072def75827c026fdff2153e5e666f41d6c52752eefa5e5eedb942caacc0893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Medicine General &amp; Introductory Medical Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, Lesley A</creatorcontrib><creatorcontrib>Oldman, Anna</creatorcontrib><creatorcontrib>McQuay, Henry J</creatorcontrib><creatorcontrib>Moore, R Andrew</creatorcontrib><creatorcontrib>Derry, Sheena</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cochrane database of systematic reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, Lesley A</au><au>Oldman, Anna</au><au>McQuay, Henry J</au><au>Moore, R Andrew</au><au>Derry, Sheena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Eletriptan for acute migraine</atitle><jtitle>Cochrane database of systematic reviews</jtitle><date>2001-07-23</date><risdate>2001</risdate><volume>2001</volume><issue>3</issue><eissn>1469-493X</eissn><abstract>Migraine is a significant health problem affecting about 18% of women and 6% of men, and many drugs are available for its treatment. Eletriptan is a new drug which will soon be available by prescription. Data from trials undertaken by the manufacturer and analysed independently by the reviewers showed that treatment of an acute migraine attack with eletriptan 20 mg, 40 mg or 80 mg provided significant pain relief from 0.5 to 24 hours. The incidence of adverse effects was dose‐related, with patients taking eletriptan 80 mg reporting more adverse effects.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>17636718</pmid><doi>10.1002/14651858.CD003224.pub2</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1469-493X
ispartof Cochrane database of systematic reviews, 2001-07, Vol.2001 (3)
issn 1469-493X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6564092
source Alma/SFX Local Collection
subjects Medicine General & Introductory Medical Sciences
title Eletriptan for acute migraine
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T03%3A09%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Eletriptan%20for%20acute%20migraine&rft.jtitle=Cochrane%20database%20of%20systematic%20reviews&rft.au=Smith,%20Lesley%20A&rft.date=2001-07-23&rft.volume=2001&rft.issue=3&rft.eissn=1469-493X&rft_id=info:doi/10.1002/14651858.CD003224.pub2&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_6564092%3C/pubmedcentral%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3472-ea072def75827c026fdff2153e5e666f41d6c52752eefa5e5eedb942caacc0893%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/17636718&rfr_iscdi=true